{"pageContent": "Objectives: Improvements in quality of life (QoL) and disease-related symptoms are key goals in the treatment of hormone refractory prostate cancer (HRPC). Our aim was to evaluate the impact of gefitinib on QoL of patients with HRPC.", "metaData": {"source": "Stromal-epithelial measurements of prostate cancer in native Japanese and Japanese-American men\nhttps://pubmed.ncbi.nlm.nih.gov/15303120/"}}